What is SolasCure?
Founded in 2017 and based in the United Kingdom, SolasCure Limited is dedicated to enhancing patient outcomes and reducing healthcare costs through innovative wound care products. Their flagship product, Aurase, is a hydrogel containing a proprietary enzyme derived from medical maggots. This advanced formulation is designed to accelerate wound cleaning, thereby improving patient well-being and streamlining healthcare processes. The company's focus on leveraging biotechnological solutions for chronic wound management positions it as a key player in the healthtech industry.
How much funding has SolasCure raised?
SolasCure has raised a total of $35.8M across 3 funding rounds:
Series A
$20.8M
Unspecified
$1.6M
Series B
$13.4M
Series A (2021): $20.8M with participation from Eva Pharma, BRAIN Biotech AG, Seneca Partners, Development Bank of Wales, Bionova Capital, Jonathan Milner, and François Fournier
Unspecified (2021): $1.6M led by Seneca Partners
Series B (2023): $13.4M supported by Seneca Partners, Eva Pharma, Wealth Club, and Brain
Key Investors in SolasCure
Seneca Partners
Seneca Partners are specialist funders and advisers to small and medium sized businesses, providing capital, advice, and support to SMEs ready for their next growth phase. They specialize in supporting profitable businesses requiring a cash injection for expansion.
Eva Pharma
EVA Pharma is a leading Egyptian pharmaceutical company focused on innovating healthcare solutions and addressing unmet medical needs across various therapeutic areas. They have a strong commitment to partnerships that facilitate access to life-saving treatments.
Wealth Club
Wealth Club offers experienced investors advanced investment opportunities, acting as a platform for sophisticated investment strategies. They provide access to a range of financial products and services for their clientele.
What's next for SolasCure?
With the recent major strategic investment, SolasCure is poised for accelerated growth and market penetration. This capital infusion is expected to fuel further research and development, scale manufacturing capabilities, and expand commercialization efforts for Aurase. The company's trajectory suggests a move towards broader adoption within healthcare systems, potentially solidifying its position as a leader in enzyme-based wound care solutions. Future developments may include strategic partnerships to enhance distribution networks and explore new therapeutic applications for their enzyme technology.
See full SolasCure company page
